20 patents
Utility
Inhibitors of Mek Kinase
28 Dec 23
Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
Toufike KANOUNI, Robert S. KANIA, Jason M. COX
Filed: 15 Jun 23
Utility
Inhibitors of Fibroblast Growth Factor Receptor Kinases
23 Nov 23
Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA
Filed: 4 Jun 21
Utility
Inhibitors of Raf Kinases
28 Sep 23
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
Filed: 3 Feb 23
Utility
Inhibitors of Mek Kinase
7 Sep 23
Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
Toufike KANOUNI, Robert S. KANIA, Jason M. COX
Filed: 27 Feb 23
Utility
Treatment of Cancer with a Raf Inhibitor
17 Aug 23
Provided herein are compositions and methods for the treatment of a cancer.
Aleksandra FRANOVIC, Eric MARTIN, Nichol L. G. MILLER, Eric MURPHY, Richard Thomas WILLIAMS, Ken KOBAYASHI
Filed: 6 Apr 23
Utility
Inhibitors of Met Kinase
13 Jul 23
Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
Xiaohu S. OUYANG, Toufike KANOUNI, John S. TYHONAS, Jason M. COX, Robert S. KANIA
Filed: 14 Dec 22
Utility
Inhibitors of Raf Kinases
16 Mar 23
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, Eric A. MURPHY, Lee D. ARNOLD, John TYHONAS
Filed: 20 Mar 20
Utility
Inhibitors of Fibroblast Growth Factor Receptor Kinases
16 Mar 23
Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA, Jason M. COX
Filed: 23 Mar 22
Utility
Treatment of Cancer with CDK12/13 Inhibitors
9 Mar 23
Provided herein are compositions and methods for the treatment of a triple-negative breast cancer, ovarian cancer and castration-resistant prostate cancer.
Eric A. MURPHY, John TYHONAS, Noelito TIMPLE, Toufike KANOUNI, Lee D. ARNOLD, Elisabeth GARDINER, Eric MARTIN
Filed: 23 Dec 20
Utility
Inhibitors of Cyclin-dependent Kinases
8 Dec 22
Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
Filed: 16 Jul 20
Utility
Inhibitors of Raf Kinases
10 Nov 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, Eric MURPHY, Jason COX, Robert KANIA
Filed: 6 May 22
Utility
Inhibitors of Raf Kinases
27 Oct 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
Filed: 26 Apr 22
Utility
Inhibitors of Raf Kinases
14 Apr 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, Eric MURPHY, Jason COX, Robert KANIA
Filed: 11 Oct 21
Utility
Inhibitors of Raf Kinases
24 Mar 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
Filed: 16 Sep 21
Utility
Inhibitors of Raf Kinases
30 Sep 21
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY
Filed: 25 Mar 21
Utility
Inhibitors of Raf Kinases
12 Aug 21
Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
Stephen W. KALDOR, Toufike KANOUNI, Lee ARNOLD
Filed: 4 Feb 21
Utility
Inhibitors of Cyclin-dependent Kinases
6 May 21
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
Filed: 11 Nov 20
Utility
Inhibitors of Cyclin-dependent Kinases
25 Feb 21
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Lee ARNOLD, Stephen W. KALDOR, Eric A. MURPHY
Filed: 2 May 19
Utility
Inhibitors of Raf Kinases
4 Nov 20
Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
Stephen W. KALDOR, Toufike KANOUNI, Lee ARNOLD
Filed: 29 Apr 20
Utility
Inhibitors of Cyclin-dependent Kinases
22 Jan 20
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
Filed: 27 Jun 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first